Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome

M. Witsch-Baumgartner, B. U. Fitzky, M. Ogorelkova, H. G. Kraft, F. F. Moebius, H. Glossmann, U. Seedorf, G. Gillessen-Kaesbach, G. F. Hoffmann, P. Clayton, R. I. Kelley, G. Utermann

Research output: Contribution to journalArticle

Abstract

Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96%), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.

Original languageEnglish (US)
Pages (from-to)402-412
Number of pages11
JournalAmerican Journal of Human Genetics
Volume66
Issue number2
DOIs
StatePublished - 2000

Fingerprint

Smith-Lemli-Opitz Syndrome
Genetic Association Studies
Sterols
Oxidoreductases
Mutation
Genes
Cholesterol
Missense Mutation
Endoplasmic Reticulum
Alleles
Phenotype
Protein Stability
HEK293 Cells
Homozygote
Intellectual Disability

ASJC Scopus subject areas

  • Genetics

Cite this

Witsch-Baumgartner, M., Fitzky, B. U., Ogorelkova, M., Kraft, H. G., Moebius, F. F., Glossmann, H., ... Utermann, G. (2000). Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. American Journal of Human Genetics, 66(2), 402-412. https://doi.org/10.1086/302760

Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. / Witsch-Baumgartner, M.; Fitzky, B. U.; Ogorelkova, M.; Kraft, H. G.; Moebius, F. F.; Glossmann, H.; Seedorf, U.; Gillessen-Kaesbach, G.; Hoffmann, G. F.; Clayton, P.; Kelley, R. I.; Utermann, G.

In: American Journal of Human Genetics, Vol. 66, No. 2, 2000, p. 402-412.

Research output: Contribution to journalArticle

Witsch-Baumgartner, M, Fitzky, BU, Ogorelkova, M, Kraft, HG, Moebius, FF, Glossmann, H, Seedorf, U, Gillessen-Kaesbach, G, Hoffmann, GF, Clayton, P, Kelley, RI & Utermann, G 2000, 'Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome', American Journal of Human Genetics, vol. 66, no. 2, pp. 402-412. https://doi.org/10.1086/302760
Witsch-Baumgartner, M. ; Fitzky, B. U. ; Ogorelkova, M. ; Kraft, H. G. ; Moebius, F. F. ; Glossmann, H. ; Seedorf, U. ; Gillessen-Kaesbach, G. ; Hoffmann, G. F. ; Clayton, P. ; Kelley, R. I. ; Utermann, G. / Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. In: American Journal of Human Genetics. 2000 ; Vol. 66, No. 2. pp. 402-412.
@article{eefc699fa274433987f6f9c2dfcdee37,
title = "Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome",
abstract = "Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96{\%}), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.",
author = "M. Witsch-Baumgartner and Fitzky, {B. U.} and M. Ogorelkova and Kraft, {H. G.} and Moebius, {F. F.} and H. Glossmann and U. Seedorf and G. Gillessen-Kaesbach and Hoffmann, {G. F.} and P. Clayton and Kelley, {R. I.} and G. Utermann",
year = "2000",
doi = "10.1086/302760",
language = "English (US)",
volume = "66",
pages = "402--412",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Mutational spectrum in the Δ7-sterol reductase gene and genotype- phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome

AU - Witsch-Baumgartner, M.

AU - Fitzky, B. U.

AU - Ogorelkova, M.

AU - Kraft, H. G.

AU - Moebius, F. F.

AU - Glossmann, H.

AU - Seedorf, U.

AU - Gillessen-Kaesbach, G.

AU - Hoffmann, G. F.

AU - Clayton, P.

AU - Kelley, R. I.

AU - Utermann, G.

PY - 2000

Y1 - 2000

N2 - Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96%), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.

AB - Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96%), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.

UR - http://www.scopus.com/inward/record.url?scp=0034134128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034134128&partnerID=8YFLogxK

U2 - 10.1086/302760

DO - 10.1086/302760

M3 - Article

VL - 66

SP - 402

EP - 412

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 2

ER -